Nicotinamide Riboside in Ulcerative Colitis

Description

This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).

Conditions

Ulcerative Colitis

Study Overview

Study Details

Study overview

This is a randomized, double-blind pilot study of Nicotinamide Riboside (NR) in Pediatric-onset Ulcerative Colitis (UC).

Nicotinamide Riboside in Ulcerative Colitis

Nicotinamide Riboside in Ulcerative Colitis

Condition
Ulcerative Colitis
Intervention / Treatment

-

Contacts and Locations

Pittsburgh

UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States, 15224

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pediatric patients (≤18yo);
  • * Diagnosis of mild to moderate ulcerative colitis as determined by Pediatric Ulcerative Colitis Activity Index (PUCAI) and endoscopic scoring (Mayo) at the time of colonoscopy;
  • * Although the investigators will target newly diagnosed patients (therefore, treatment naïve), patients with established disease will also be enrolled.
  • * Patients with acute severe ulcerative colitis;
  • * Concurrent gastrointestinal infection (ie. Clostridium difficile, Cytomegalovirus, etc.);
  • * A diagnosis of Crohn's disease;
  • * Indeterminate colitis/IBD-U;
  • * In general, patients that have been treated with steroids or antibiotics in the past three months. Patients on Biologic medications may be enrolled if their dose has been stable for at least three months. Final determination of eligibility will be at the discretion of the treating investigator. After the initiation of the study, subjects may receive any medication to treat their disease as dictated by their care providers;
  • * Patients who have other chronic inflammatory/autoimmune disorders or prior malignancy;
  • * Pregnant women (All women of childbearing age will be required to use contraception at the time of inclusion).
  • * Patients with existing renal or hepatic dysfunction;
  • * Per standard of care guidance, subjects with platelets \<50,000 do not undergo endoscopy and, therefore, are not eligible.

Ages Eligible for Study

to 18 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pittsburgh,

Kevin Mollen, PRINCIPAL_INVESTIGATOR, University of Pittsburgh

Study Record Dates

2025-12-31